Devyser Diagnostics Ab · OMXSTO:DVYSR
Devyser Diagnostics Ab — Q3 2026 Earnings Presentation
22 slides from Devyser Diagnostics Ab's earnings presentation, Nov 3, 2026
Slide 1: Earnings call Q3 2026
Devyser Earnings call Q3 2026 November 3rd, 2026
Slide 2: Today's presenters
Today’s presenters Jan Wahlström Niklas Axelsson CEO CFO
Slide 3: Q3 2026: Improved profitability
Q3 2026: Improved profitability
Slide 4: Q3 highlights & subsequent events
Q3 highlights & subsequent events · Considering inventory build-up effect at our largest distributor impacting sales in Q3, solid underlying sales performance at 59.7 MSEK · After one-off inventory effect in Q2, bounce back to a healthy gross margin at 83% · Thanks to an enhanced organizational effi
Slide 5: Growth continues in core segments
Growth continues in core segments · Sales of 181.7 MSEK generated during first nine months with growth driven by: · NGS product launches – CFTR and Thalassemia · Hereditary product sales in the US · Continued strengthened position in Italy, exemplified by recent renewed NGS tender win corresponding
Slide 6: MolDx progress
MolDx progress · MolDx application for kidney transplant follow up as a service in the US ongoing · Estimated approval before the end of the year · Preparations ongoing for commercialization and channel strategy ahead of approval
Slide 7: Third quarter 2026
Third quarter 2026
Slide 8: Third quarter
Third quarter ▪ Revenue • Sales 59.7 MSEK (56.4 MSEK) • Growth +5.8%, F/X adj. +5.7% 8
Slide 9: Rolling 12 months net sales
Rolling 12 months net sales SEK million 300 250 200 150 100 50 Dvysr.
Slide 10: Sales by region
Sales by region Q3 Q3 % of Q3 % of Q3 % Growth 2026 2025 2026 2025 QoQ EMEA 50,3 47,7 84,3% 84,6% 5,3% Asia-Pacific 2,3 1,7 3,9% 3,1% 33,0% North and South America 7,1 6,9 11,9% 12,3% 2,6% Total 59,7 56,4 100,0% 100,0% 5,8% 10
Slide 11: Sales by sales channel
Sales by sales channel Q3 Q3 % of Q3 % of Q3 % Growth 2026 2025 2026 2025 QoQ Direct sales 45,1 42,5 75,5% 75,3% 6,0% Distributor sales 14,6 13,9 24,5% 24,7% 5,3% Total 59,7 56,4 100,0% 100,0% 5,8% 11
Slide 12: Third quarter
Third quarter ▪ Revenue • Sales 59.7 MSEK (56.4 MSEK) • Growth +5.8%, F/X adj. +5.7% ▪ Gross margin 83.0% (75.0%) 12
Slide 13: Third quarter
Third quarter ▪ Revenue • Sales 59.7 MSEK (56.4 MSEK) • Growth +5.8%, F/X adj. +5.7% ▪ Gross margin 83.0% (75.0%) ▪ EBIT • 7.1 MSEK (1.3) 13
Slide 14: Third quarter
Third quarter ▪ Revenue • Sales 59.7 MSEK (56.4 MSEK) • Growth +5.8%, F/X adj. +5.7% ▪ Gross margin 83.0% (75.0%) ▪ EBIT • 7.1 MSEK (1.3) ▪ Cash • 88.7 MSEK in liquidity (84.9) • Cash flow from operating activities: +22.0 MSEK (-0.5) 14
Slide 15: Highlights Q3 and Commercial outlook
Highlights Q3 and Commercial outlook
Slide 16: Q3 commercial recap
Q3 commercial recap • Overall, solid sales performance • Strong development in hereditary sales (both in EU & US) • Transplant products still impacted by inventory build-up at our largest distributor • High growth in US sales with our direct business • Launched One Lambda Devyser Chimerism Plus with
Slide 17: Reagent rental deals
Reagent rental deals · First commercial reagent rental agreement signed in August with a lab in Italy, within the Illumina collaboration · The customer replaces an upfront capital investment with a multi-year commitment to buy reagents, which gives us recurring revenue with higher predictability · W
Slide 18: Update on Thermo Fisher Scientific
Update on Thermo Fisher Scientific ▪ Since quarter-end, launched One Lambda Devyser Chimerism Plus with Thermo Fisher – a next-generation chimerism monitoring solution that reduces workflow-related error risk while improving lab efficiency and usability ▪ Weak sales both in Q2 and Q3 due to distribu
Slide 19: Accept Heart & Lung – Expansion of the addressable market
Accept Heart & Lung – Expansion of the addressable market Heart & Lung transforms Accept from a kidney-focused product into a broader solid-organ transplant monitoring platform Importance Market impact ▪ Potential to reduce reliance on invasive Number of annual transplants: biopsies Kidney: ~27k Hea
Slide 20: Going forward
Going forward • Underlying demand remains strong in our direct and other distributor markets • One-time inventory correction at our largest distributor: weaker sales for the rest of 2026, then more normal levels during 2027 • Our aim: profitable growth, faster than the underlying market • Focus on o
Slide 21: Q&A
O&A Dvysr.
Slide 22: Thank you!
Thank you! Connect with us www.devyser.com A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatica